CSIMarket
 


Gt Biopharma Inc   (GTBP)
Other Ticker:  
 
 

GTBP's Operating Income Growth by Quarter and Year

Gt Biopharma Inc 's Operating Income results by quarter and year




GTBP Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -36.74 -6.46 -1.95
III Quarter September 3.12 7.02 -4.38 -1.56
II Quarter June 3.62 3.01 29.00 -1.07
I Quarter March 3.67 5.44 11.34 -0.87
FY   10.41 -21.27 29.50 -5.45



GTBP Operating Income third quarter 2023 Y/Y Growth Comment
Gt Biopharma Inc reported drop in Operating Income in the third quarter 2023 by -55.53% to $ 3.12 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Gt Biopharma Inc 's Operating Income compares unfavorably to the Company's average Operating Income decline of -37.32%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 32 other companies have achieved higher Operating Income growth. While Gt Biopharma Inc ' s Operating Income meltdown of -55.53% ranks overall at the positon no. 1971 in the third quarter 2023.

Explain Operating Income growth


GTBP Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September -55.53 % - - -
II Quarter June 20.27 % -89.62 % - -
I Quarter March -32.54 % -52.03 % - -
FY   - - - -

Financial Statements
Gt Biopharma Inc 's third quarter 2023 Operating Income $ 3.12 millions GTBP's Income Statement
Gt Biopharma Inc 's third quarter 2022 Operating Income $ 7.02 millions Quarterly GTBP's Income Statement
New: More GTBP's historic Operating Income Growth >>


GTBP Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September -13.76 % 133.22 % - -
II Quarter June -1.36 % -44.67 % 155.73 % -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #33
Healthcare Sector #130
Overall #1971

Operating Income Y/Y Growth Statistics
High Average Low
20.14 % -37.32 % -81.24 %
(Jun 30 2023)   (Mar 31 2022)
Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #33
Healthcare Sector #130
Overall #1971
Operating Income Y/Y Growth Statistics
High Average Low
20.14 % -37.32 % -81.24 %
(Jun 30 2023)   (Mar 31 2022)

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Gt Biopharma Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
155.82 % 45.85 % -44.62 %
(Mar 31 2021)  


GTBP's III. Quarter Q/Q Operating Income Comment
In the III. Quarter 2023 Gt Biopharma Inc realized drop in Operating Income from the second quarter by -13.76% to $ 3.12 millions, from $ 3.62 millions achived in the previous reporting period.

Even seasonal factors which commonly fuel III. Quarter 2023 Operating Income, could not recover the III. Quarter for the Gt Biopharma Inc , Mia Thompson, a business insider from New York pointed out, she cited little skepticism towards GTBP's direction, she sees new challenges onward for the Major Pharmaceutical Preparations's company and wrote that average quarter on quarter Operating Income growth is at 45.85% for the Major Pharmaceutical Preparations's company.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Operating Income quarter on quarter growth. While Gt Biopharma Inc 's Operating Income growth quarter on quarter, overall rank is 1606.


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #111
Overall #1606
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #111
Overall #1606
Operating Income Q/Q Growth Statistics
High Average Low
155.82 % 45.85 % -44.62 %
(Mar 31 2021)  


GTBP's III. Quarter Q/Q Operating Income Comment
In the III. Quarter 2023 Gt Biopharma Inc realized drop in Operating Income from the previous quarter by -13.76% to $ 3.12 millions, from $ 3.62 millions released in the previous reporting period.

Those cyclical influence which commonly energize III. Quarter 2023 performance, could not rescue the III. Quarter for the Gt Biopharma Inc , Mia Thompson, a business insider from New York wrote, she detected new headwinds down the road for GTBP.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Operating Income quarter on quarter growth. While Gt Biopharma Inc 's Operating Income growth quarter on quarter, overall rank is 1606.


Gt Biopharma Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Operating Income 12 Months Ending $ -26.33 $ -22.43 $ -23.03 $ -21.26 $ 9.02
Y / Y Operating Income Growth (TTM) - - - - -73.47 %
Year on Year Operating Income Growth Overall Ranking # 2003 # 2134 # 117 # 0 # 1411
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Gt Biopharma Inc realized trailing twelve months Operating Loss of $ -26 millions, in the Sep 30 2023, compare to Operating Income of $ 9 millions a year ago.

In the Healthcare sector 132 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 2003, from total ranking in previous quarter at 2134.

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 133
Overall # 2003

Operating Income TTM Y/Y Growth Statistics
High Average Low
249.01 %
-114.88 %
-391.79 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Gt Biopharma Inc realized trailing twelve months Operating Loss of $ -26 millions, in the Sep 30 2023, compare to Operating Income of $ 9 millions a year ago.

In the Healthcare sector 132 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 2003, from total ranking in previous quarter at 2134.

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 133
Overall # 2003

Operating Income TTM Y/Y Growth Statistics
High Average Low
249.01 %
-114.88 %
-391.79 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
GTBP's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for GTBP's Competitors
Operating Income Growth for Gt Biopharma Inc 's Suppliers
Operating Income Growth for GTBP's Customers

You may also want to know
GTBP's Annual Growth Rates GTBP's Profitability Ratios GTBP's Asset Turnover Ratio GTBP's Dividend Growth
GTBP's Roe GTBP's Valuation Ratios GTBP's Financial Strength Ratios GTBP's Dividend Payout Ratio
GTBP's Roa GTBP's Inventory Turnover Ratio GTBP's Growth Rates GTBP's Dividend Comparisons



Companies with similar Operating Income drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Bio techne Corp-0.81%$ -0.808 millions
The Pennant Group Inc -1.16%$ -1.162 millions
Bio rad Laboratories Inc -1.99%$ -1.990 millions
Corcept Therapeutics Inc-2.37%$ -2.371 millions
Mettler toledo International Inc -3.07%$ -3.068 millions
Tenet Healthcare Corp-4.70%$ -4.698 millions
West Pharmaceutical Services Inc -4.78%$ -4.780 millions
Bruker Corporation-5.18%$ -5.179 millions
Henry Schein Inc-5.21%$ -5.213 millions
Hologic Inc-5.96%$ -5.962 millions
Sonida Senior Living Inc -6.27%$ -6.269 millions
Abbott Laboratories-6.95%$ -6.949 millions
Gilead Sciences Inc -7.54%$ -7.543 millions
Vertex Pharmaceuticals Inc-7.86%$ -7.864 millions
Bristol myers Squibb Company-9.18%$ -9.183 millions
Regeneron Pharmaceuticals Inc -9.21%$ -9.210 millions
National Research Corporation-10.39%$ -10.388 millions
Quest Diagnostics Inc-12.76%$ -12.755 millions
Bausch and Lomb Corp-13.04%$ -13.043 millions
Carlisle Companies Incorporated-13.87%$ -13.871 millions
Pediatrix Medical Group Inc -15.01%$ -15.015 millions
Community Health Systems Inc -15.20%$ -15.196 millions
Teva Pharmaceutical Industries Limited-15.27%$ -15.274 millions
Zynex inc -16.36%$ -16.362 millions
Entera Bio Ltd -16.72%$ -16.719 millions
Pacira Biosciences inc -16.76%$ -16.760 millions
Viatris Inc -19.35%$ -19.354 millions
Royalty Pharma Plc-21.21%$ -21.210 millions
Luna Innovations Inc-22.06%$ -22.057 millions
Avantor Inc -23.79%$ -23.785 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com